
Relevant Interviews, Webinar and Trial Updates posted by CRISPR Medicine News.
Always stay updated with the free CMN Newsletter.
Capstan Therapeutics
Company Type: Therapeutic development
Main focus: Developing treatments for various diseases through engineering immune cells and targeting pathogenic cells with mRNA-encoded gene-editing technology
Company stage: Pre-clinical
Diseases: Cancer, autoimmune disorders, fibrosis, and monogenic blood disorders
Genome-editing tool: mRNA-encoded gene editing machinery
Funding stage: Series B
Location: San Diego, California, USA
Website: https://www.capstantx.com/
Pipeline:
Partners:

Capstan Therapeutics is a biotechnology company dedicated to advancing new therapies through targeted and precise in vivo gene- and cell engineering. Their approach to disease treatments follows two distinct pathways; engineering immune cells and targeting pathogenic cells through in vivo gene editing. Capstan’s core technology revolves around targeted lipid nanoparticles (tLNPs) carrying disease-specific payloads.